Nemaura Medical has announced that it now includes insulin under its DuoPack commercial license agreement.
Nemaura Medical entered into a commercial agreement in September 2021 with MySugarWatch DuoPack Limited (MSWDL), under which Nemaura’s non-invasive, wearable skin patch sensors are paired with prescription-only medicines for Type 2 diabetes. This combination of sensors and medicine aims to provide a ‘one-stop shop’ supported by a holistic care approach.
The inclusion of insulin in our agreement with MSWDL means patients with type 2 diabetes will have access to a CGM-guided insulin dose titration care model that is designed to reduce hypoglycemic episodes and hospital admissions while improving long-term outcomes,” said Nemaura CEO Dr. Faz Chowdhury. “Moreover, it uniquely avoids a potentially bruised, slow-to-heal, infection-prone, needle-induced skin puncture wound in older patients at the site of a CGM sensor skin application.”
To read more, CLICK HERE.
